Home / Medical Care in China / Hematology / Multiple myeloma

Medical Care in China

Multiple myeloma
Treatment in China

Provide a clear and complete coordinated pathway from expert assessment to treatment and rehabilitation.

Get a Care Plan and Cost Estimate

The coverage of blood diseases is broadincluding anemia, leukemia, lymphoma, and myeloma.

Precise blood diagnosisclarifies the condition through bone marrow, molecular and genetic examinations.

Cell therapy selectionCAR-T and other therapies are evaluated for eligible patients.

Transplantation therapy supportcovers hematopoietic stem cell transplantation and related management.

Condition Guide

About Multiple myeloma

Understand the condition, common triggers and treatment options that may require specialist assessment.

Disease Introduction

Multiple myeloma is a hematologic malignancy caused by the malignant proliferation of plasma cells, manifesting as bone pain, pathological fractures, anemia, kidney damage, hypercalcemia, and recurrent infections. It is highly prevalent in the elderly population. While a complete cure is currently difficult, the emergence of drugs such as proteasome inhibitors, immunomodulators, CD38 monoclonal antibodies, dual antibodies, and CAR-T therapy has ushered in an era of long-term management as a chronic disease.

Cutting-edge high-precision diagnostic and treatment technologies

CD38 monoclonal antibody cornerstone : Daratumumab (CD38 monoclonal antibody) subcutaneous injection formulation is widely used for newly diagnosed and relapsed/refractory myeloma; Elsartuximab was approved in China in January 2025, further enriching first-line options.
Dara-VRd as first-line treatment : Dara-VRd in combination with bortezomib, lenalidomide, and dexamethasone is the preferred induction regimen for newly diagnosed transplant patients, significantly improving deep remission rate and minimal residual disease clearance rate.
Bispecific antibodies approved : Teratoside, Enatoside, Taquitoside and other BCMA×CD3 bispecific antibodies were successively approved in China from 2024 to 2025 for patients with multiple relapsed or refractory diseases, without waiting for cell preparation and with higher accessibility.
BCMA CAR-T : BCMA-targeted CAR-T cell therapy has brought deep and durable remission to relapsed and refractory patients and has been routinely carried out in many centers in China.
New targets such as triple antibodies : Trispecific antibodies targeting BCMA and CD38 (ISB 2001, etc.) are under investigation. Combining them with γ-secretase inhibitors can enhance BCMA expression and further improve efficacy.

Care Overview

Multiple myeloma Treatment in China

The medical team will develop a personalized protocol based on the pathology type, stage, genetic test, previous treatment history, and the patient's physical condition.

1. Newly diagnosed stratified induction : Suitable transplant recipients undergo deep induction with Dara-VRd and other methods before autologous transplantation, followed by maintenance with daratumumab + lenalidomide; unsuitable transplant recipients use a combination daratumumab regimen.
2. Relapse and re-line treatment : For the first relapse, select drugs with different mechanisms of action, such as CD38 monoclonal antibody, carfilzomib, pomalidomide, and celiniso, based on the previous line of treatment, and evaluate the timing of dual anti-antibody or CAR-T therapy.
3. Convenient dual antibody therapy : Patients with multiple relapses can choose subcutaneous/intravenous BCMA bispecific antibody therapy, which has a rapid onset of action, requires no collection and preparation, and monitors cytokine release and infection risk throughout the process.
4. Deep CAR-T remission : BCMA CAR-T is evaluated in relapsed and refractory patients. After treatment, immune reconstitution and long-term relapse are monitored in a standardized manner to strive for treatment-free remission.
5. Comprehensive supportive care : Combined treatment with bisphosphonates or denosumab to prevent and treat bone diseases, manage anemia and kidney function, standardize anti-infection and vaccination, and comprehensively improve quality of life.

1. Significantly extended survival : In the era of new drugs, the median overall survival of myeloma patients has been significantly extended, and most patients have entered into chronic disease management with long-term survival with the disease.
2. Benefits of deep remission : CD38 monoclonal antibodies, bispecific antibodies and CAR-T therapy improve the rate of minimal residual disease seroconversion, and deep remission is directly associated with longer progression-free survival.
3. Seamless integration of treatment plans : a multi-tiered approach including proteasome inhibitors, immunomodulators, monoclonal antibodies, bispecific antibodies, and CAR-T therapy, providing multiple effective options even after relapse.
4. Individualized stratification : Drug selection is based on cytogenetic risk, age, and physical condition, taking into account both efficacy and tolerability, so that elderly patients can also benefit.
5. Improved accessibility of domestically produced drugs : Domestically produced generic and innovative drugs have been successively approved and included in medical insurance, significantly reducing the burden of long-term treatment and continuously improving patient accessibility.

Network of partner hospitals

Recommended Hospitals

Selected leading medical centers with strong specialties and international patient services.

Institute of Hematology, Chinese Academy of Medical Sciences (Chinese Academy of Medical Sciences Institute of Hematology)

Beijing · Partner Hospital

Institute of Hematology, Chinese Academy of Medical Sciences (Chinese Academy of Medical Sciences Institute of Hematology)

Hematology

The institute is the supporting unit of the National Clinical Research Center for Hematological Diseases, the National Stem Cell Engineering Technology Research Center, and the Stem Cell Medicine Center of the Chinese Academy of Medical Sciences. It is also the executive department of the World Federation of Hemophilia (China), the supporting unit of the National Hemophilia Case Information Management Center, and is leading the establishment of the National Quality Control Center for Hematology. For many consecutive years, it has ranked first in the Fudan University ranking of hematology disciplines, and its CAR-T cell therapy center for hematological diseases ranks second in the country.

Year Founded: 1957
Beds: 1540

Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine

Shanghai · Partner Hospital

Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine

OncologyHematologyGastroenterologyUrologyInternal MedicineSurgeryOrthopedics

Ruijin Hospital consistently ranks among the top four hospitals in China according to the comprehensive hospital rankings released by the Fudan University Hospital Management Institute. It is a national medical center construction unit and possesses national-level platforms such as the National Clinical Research Center for Metabolic Diseases and the National Clinical Research Center for Hematological Diseases. The hospital currently has four key disciplines designated by the Ministry of Education (Hematology, Endocrinology and Metabolic Diseases, Cardiology, and Neurology), 22 national key clinical specialties, and one national key laboratory for medical genomics. The hospital has been awarded the title of National Civilized Unit four times consecutively and has received honors such as the National May 1st Labor Medal and the National Advanced Collective of the Health System. It is also a national demonstration unit for integrated traditional Chinese and Western medicine.

Year Founded: 1907
Beds: 5100

Southern Medical University Southern Hospital

Guangzhou · Partner Hospital

Southern Medical University Southern Hospital

Organ TransplantHematologyInternal MedicineCosmetic Surgery

The hospital is a national regional trauma medical center jointly constructed by the provincial and national governments, a national project unit for improving the diagnosis and treatment capabilities of difficult and complex diseases (tumors), a national regional TCM (rheumatology) treatment center, a national emergency medical rescue base, and one of the first key construction units in Guangdong Province's "Peak Climbing Plan" for high-level hospitals. It boasts 5 national key disciplines, 17 national key clinical specialties, and 4 national key clinical specialty construction projects. In the 2023 national public hospital performance evaluation, it ranked in the A+ category. In authoritative domestic hospital rankings, the hospital consistently ranks among the top 15 to 20 comprehensive hospitals nationwide, with more than ten specialties, including nephrology, infectious diseases, plastic surgery, hematology, pathology, and gastroenterology, ranking in the top ten or receiving nominations.

Year Founded: 1941
Beds: 2225

Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

Wuhan · Partner Hospital

Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

HematologyCardio-CerebrovascularUrology

The hospital ranks 9th nationwide in the Fudan University China Hospital Specialty Ranking, making it one of the strongest hospitals in Central China. Its specialties, including heart transplantation, hematology, ultrasound, nuclear medicine, anesthesiology, and cardiovascular surgery, are among the top in the country. In particular, its nuclear medicine department has consistently ranked among the top two in Fudan University's specialty rankings for many years, and its heart transplant volume has ranked first in the country for many consecutive years. The hospital is a national drug clinical trial institution and a national stem cell clinical research institution, boasting strong research capabilities.

Year Founded: 1866
Beds: 6000

Leading Specialists

Trusted Expertise Across Leading Specialties

Feng Ru

Professor, Chief Physician, Doctoral Supervisor, Deputy Director of Department, Head of Lymphoma Subspecialty

Hematology

-Research areas : pathogenesis, diagnosis and treatment of lymphoma and multiple myeloma, targeted immunotherapy, and leukemia. - Cutting-edge technologies: Dynamic monitoring of MRD for lymphoma and myeloma, and clinical research on new drugs for relapsed and refractory lymphomas. - Areas of expertise: Hodgkin's/non-Hodgkin's lymphoma, multiple myeloma, plasma cell diseases, lymphoma, leukemia. - Academic Highlights & Value: Visiting scholar experience in the United States and Japan; presided over multip

Affiliated Hospital Southern Medical University Southern Hospital

Sun Jing

Professor, Chief Physician, Doctoral Supervisor, Deputy Director of Department, Director of Hemophilia Center

Hematology

-Research areas : Hematopoietic stem cell transplantation, bleeding disorders, and hemophilia diagnosis and treatment - Cutting-edge technologies: unrelated hematopoietic stem cell transplantation, hemophilia inhibitor immune tolerance induction program/comprehensive diagnosis and treatment of hemophilia and inhibitor management (the largest hemophilia center in South China), prevention and treatment of transplant complications. - Areas of expertise: Hemophilia, von Willebrand disease, platelet disorders,

Affiliated Hospital Southern Medical University Southern Hospital

Zhang Xiaobing

Researcher, doctoral supervisor, head of the cell gene transformation platform

Hematology

Research areas : gene editing, CAR vector design, iPSC, LNP delivery technology; Cutting-edge technologies: CRISPR gene editing CAR cells, GMP construction of lentiviral vectors; Areas of expertise: CAR vector development, gene therapy; Academic highlights: National high-level talent, multiple cell therapy invention patents; Core value: Supporting the research and clinical translation of underlying vector technologies for CAR-T and gene therapy.

Affiliated Hospital Institute of Hematology, Chinese Academy of Medical Sciences (Chinese Academy of Medical Sciences Institute of Hematology)

Zhao Weili

Chief Physician, Level 2 Professor, Doctoral Supervisor, Director of Shanghai Institute of Hematology, Vice President of Ruijin Hospital

Hematology

-Research areas : lymphoma immunotherapy, CAR-T cell therapy clinical research, and real-world CAR-T studies in Asian populations. - Cutting-edge technologies: CAR-T stratified treatment system for relapsed and refractory large B-cell lymphoma; CAR-T adverse reaction MDT management model. - Areas of expertise: Diffuse large B-cell lymphoma, primary mediastinal B-cell lymphoma, follicular lymphoma, and other B-cell non-Hodgkin lymphomas. - Academic Highlights: Led a multicenter real-world study of CAR-T th

Affiliated Hospital Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine

Liu Qifa

Level 2 Professor, Chief Physician, Doctoral Supervisor, Academic Leader, Director of the Institute of Hematology

Hematology

Research areas : Molecular pathogenesis of leukemia, hematopoietic stem cell transplantation, tumor immunotherapy, and prevention and treatment of infections in immunocompromised hosts. - Cutting-edge technologies: Haploidentical hematopoietic stem cell transplantation; MICM precision stratification therapy for leukemia; precision stratification therapy for acute leukemia (rewriting the NCCN/ELN guidelines); combined haploidentical and umbilical cord blood transplantation (Lancet RCT); MSC prevention of G

Affiliated Hospital Southern Medical University Southern Hospital

Li Junmin

Head of Hematology

Hematology

Research areas : hematologic malignancies and hematologic immune diseases; construction of CAR-T clinical research system. Cutting-edge technology: creation of translational medicine wards and CAR-T clinical trial screening system. Specializes in treating: acute myeloid leukemia, multiple myeloma, and lymphoma. Academic Highlights: Led the establishment of China's first translational medicine ward in hematology; emphasized that CAR-T "is a novel immunotherapy that acts on the tumor microenvironment and ha

Affiliated Hospital Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine

Patient Stories

See the Next Step Through Patient Journeys

Lower Extremity Arteriosclerosis Obliterans - A Masterpiece for Unblocking the

CASE 01

PATIENT JOURNEY

Lower Extremity Arteriosclerosis Obliterans - A Masterpiece for Unblocking the "Silent Killer"

HematologyCardio-Cerebrovascular

Patient records Name: Carlos Silva Age: 70 Nationality: Brazil (São Paulo) Diagnosis: Lower extremity arteriosclerosis obliterans (Rutherford grade 4, long segment occlusion of the left superficial femoral artery, rest pain) Treatment Hospital: Department of Vascular Surgery, Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine Mr. Carlos is a passionate samba dancer who, even in his seventies, still enjoys swaying to the music on the streets of Rio. However, for the past six mo

View case details →

Lymphoma : While CAR-T therapy is prohibitively expensive and has long waiting times in the West: An Australian patient found an accessible

CASE 02

PATIENT JOURNEY

Lymphoma : While CAR-T therapy is prohibitively expensive and has long waiting times in the West: An Australian patient found an accessible "cure" in China.

OncologyHematology

Patient records Name: Sarah Age: 32 Nationality: Australia Diagnosis: Relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL), non-germinal center type (non-GCB), CD19 positive, relapsed after autologous stem cell transplantation. Treatment Hospital: Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences (Tianjin) In the field of cancer treatment, CAR-T cell therapy is hailed as "living medicine," bringing hope of a cure to patients with relapsed or refractory hemat

View case details →

CASE 03

PATIENT JOURNEY

When CAR-T "Failed": How a Singaporean child found a backup plan in China Patient records

Hematology

Name: Ethan (pseudonym) Age: 8 years old Nationality: Singapore Diagnosis: Relapsed/refractory B-cell acute lymphoblastic leukemia (R/R B-ALL), CD19-negative relapse after CD19 CAR-T therapy. Treatment Hospital: Shanghai Children's Medical Center In the field of childhood leukemia treatment, CAR-T cell therapy has brought hope to countless families. But when this "living drug" also fails, patients' families face an abyss of near despair. Ethan's story tells how we helped a family find a "backup plan" with

View case details →

Service Process

A clear, coordinated process for efficient cross-border care

01
Pre-Visit Services
Contact us for help organising and translating medical records, planning consultations, and finding suitable hospitals and specialists.
02
Remote Consultations
A remote consultation helps establish an initial approach to diagnosis and treatment, with a cost estimate available within 48 hours.
03
Travel Arrangements
We assist with visa applications, book flights and hotel or apartment accommodation, and arrange airport pick-up, private transport and check-in.
04
Comprehensive Support in China
We accompany you to medical appointments and provide interpreting services, help arrange specialist consultations or surgery, assist with hospital admission and discharge, and help settle medical bills.
05
Post-Visit Services
We assist with notarisation of medical expense documents, airport drop-off, organisation and translation of medical records, remote rehabilitation guidance, and coordination of international referrals.

Next Step

Get a Care Plan
and Cost Estimate.

Tell us about your diagnosis and needs, and our team will help screen the right hospital and explain the next steps.

Email:goldentcm@163.com

Multiple myeloma
Treatment in China

About Multiple myeloma

Multiple myeloma Treatment in China

Recommended Hospitals

Institute of Hematology, Chinese Academy of Medical Sciences (Chinese Academy of Medical Sciences Institute of Hematology)

Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine

Southern Medical University Southern Hospital

Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

Trusted Expertise Across Leading Specialties

Feng Ru

Sun Jing

Zhang Xiaobing

Zhao Weili

Liu Qifa

Li Junmin

Chen Saijuan

Pan Jing

Wang Jianxiang

Zhang Ruidong

Wu Runhui

Zhang Rui

Zhai Xiaowen

Shen Shuhong

See the Next Step Through Patient Journeys

Lower Extremity Arteriosclerosis Obliterans - A Masterpiece for Unblocking the "Silent Killer"

Lymphoma : While CAR-T therapy is prohibitively expensive and has long waiting times in the West: An Australian patient found an accessible "cure" in China.

When CAR-T "Failed": How a Singaporean child found a backup plan in China Patient records

A clear, coordinated process for efficient cross-border care

Pre-Visit Services

Remote Consultations

Travel Arrangements

Comprehensive Support in China

Post-Visit Services

Get a Care Plan
and Cost Estimate.

Get a Care Plan and Estimate

Multiple myelomaTreatment in China

Multiple myeloma Treatment in China

Recommended Hospitals

Institute of Hematology, Chinese Academy of Medical Sciences (Chinese Academy of Medical Sciences Institute of Hematology)

Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine

Southern Medical University Southern Hospital

Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

Trusted Expertise Across Leading Specialties

See the Next Step Through Patient Journeys

Lower Extremity Arteriosclerosis Obliterans - A Masterpiece for Unblocking the "Silent Killer"

Lymphoma : While CAR-T therapy is prohibitively expensive and has long waiting times in the West: An Australian patient found an accessible "cure" in China.

When CAR-T "Failed": How a Singaporean child found a backup plan in China Patient records

A clear, coordinated process for efficient cross-border care

Pre-Visit Services

Remote Consultations

Travel Arrangements

Comprehensive Support in China

Post-Visit Services

Get a Care Planand Cost Estimate.

Get a Care Plan and Estimate

Multiple myeloma
Treatment in China

Get a Care Plan
and Cost Estimate.